The DOI matches its Crossref record; 84 of the 85 references it cites were found in a registry or an index.
Thiazolidinediones: the Forgotten Diabetes Medications
Open accessAbstract
Purpose of Review: Thiazolidinediones (TZDs) are the only pharmacologic agents that specifically treat insulin resistance. The beneficial effects of TZDs on the cardiovascular risk factors associated with insulin resistance have been well documented. TZD use has been limited because of concern about safety issues and side effects. Recent Findings: Recent studies indicate that cardiovascular toxicity with rosiglitazone and increase in bladder cancer with pioglitazone are no longer significant issues. There are new data which show that pioglitazone treatment reduces myocardial infarctions and ischemic strokes. New data concerning TZD-mediated edema, congestive heart failure, and bone fractures improves the clinician’s ability to select patients that will have minimal significant side effects. Summary: Thiazolidinediones are now generic and less costly than pharmaceutical company–promoted therapies. Better understanding of the side effects coupled with clear benefits on the components of the insulin resistance syndrome should promote TZD use in treating patients with type 2 diabetes.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“For instance, pioglitazone lowers myocardial infarctions (MI) and ischemic strokes, according to recent findings.”
From A critical review on diabetes mellitus type 1 and type 2 management approaches: from lifestyle modification to current and novel targets and therapeutic agents. (2024) · cites this paper as [67]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“There are no pharmacologic treatments that particularly treat insulin resistance other than TZDs.”
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Insulin Resistance in Human Disease
Reaven, G. M. (1988) · Diabetes · doi:10.2337/diab.37.12.1595 · Cited by 12,154
Effect of Rosiglitazone on the Risk of Myocardial Infarction and Death from Cardiovascular Causes
Nissen, S. E., & Wolski, K. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa072761 · Cited by 4,675
Dormandy, J. A., Charbonnel, B., Eckland, D. J., Erdmann, E., Massi-Benedetti, M., Moules, I. K., Skene, A. M., Tan, M. H., Lefèbvre, P. J., Murray, G. D., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67528-9 · Cited by 4,129
Glycemic durability of rosiglitazone, metformin, or glyburide monotherapy
Kahn, S. E., Haffner, S. M., Heise, M. A., Herman, W. H., Holman, R. R., Jones, N. P., Kravitz, B. G., Lachin, J. M., O'Neill, M. C., Zinman, B., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa066224 · Cited by 2,962
Macrophages, inflammation, and insulin resistance
Olefsky, J. M., & Glass, C. K. (2010) · Annual Review of Physiology · doi:10.1146/annurev-physiol-021909-135846 · Cited by 2,733
Fat and Beyond: The Diverse Biology of PPARγ
Tontonoz, P., & Spiegelman, B. M. (2008) · Annual Review of Biochemistry · doi:10.1146/annurev.biochem.77.061307.091829 · Cited by 2,085
Weyer, C., Bogardus, C., Mott, D. M., & Pratley, R. E. (1999) · Journal of Clinical Investigation · doi:10.1172/jci7231 · Cited by 1,940
Ford, E. S. (2005) · Diabetes Care · doi:10.2337/diacare.28.7.1769 · Cited by 1,718
Islet cell failure in type 2 diabetes
Prentki, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29103 · Cited by 1,690
Basal insulin and cardiovascular and other outcomes in dysglycemia
The ORIGIN Trial Investigators (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1203858 · Cited by 1,636
Alexander, C. M., Landsman, P. B., Teutsch, S. M., & Haffner, S. M. (2003) · Diabetes · doi:10.2337/diabetes.52.5.1210 · Cited by 1,475
Home, P. D., Pocock, S. J., Beck-Nielsen, H., Curtis, P. S., Gomis, R., Hanefeld, M., Jones, N. P., Komajda, M., & McMurray, J. J. (2009) · The Lancet · doi:10.1016/s0140-6736(09)60953-3 · Cited by 1,393
Metformin—mode of action and clinical implications for diabetes and cancer
Pernicova, I., & Korbonits, M. (2014) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2013.256 · Cited by 1,393
Insulin action and resistance in obesity and type 2 diabetes
Czech, M. P. (2017) · Nature Medicine · doi:10.1038/nm.4350 · Cited by 1,258
Lim, E. L., Hollingsworth, K. G., Aribisala, B. S., Chen, M. J., Mathers, J. C., & Taylor, R. (2011) · Diabetologia · doi:10.1007/s00125-011-2204-7 · Cited by 1,164
Metabolic effects of metformin in non-insulin-dependent diabetes mellitus
Stumvoll, M., Nurjhan, N., Perriello, G., Dailey, G., & Gerich, J. E. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330903 · Cited by 1,148
Metabolic response to sodium-glucose cotransporter 2 inhibition in type 2 diabetic patients
Ferrannini, E., Muscelli, E., Frascerra, S., Baldi, S., Mari, A., Heise, T., Broedl, U. C., & Woerle, H.-J. (2014) · Journal of Clinical Investigation · doi:10.1172/jci72227 · Cited by 1,134
Ectopic Fat in Insulin Resistance, Dyslipidemia, and Cardiometabolic Disease
Shulman, G. I. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1011035 · Cited by 1,126
Pioglitazone after Ischemic Stroke or Transient Ischemic Attack
Kernan, W. N., Viscoli, C. M., Furie, K. L., Young, L. H., Inzucchi, S. E., Gorman, M., Guarino, P. D., Lovejoy, A. M., Peduzzi, P. N., Conwit, R., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1506930 · Cited by 1,124
Disordered lipid metabolism and the pathogenesis of insulin resistance.
Savage, D. B., Petersen, K. F., & Shulman, G. I. (2007) · Physiological Reviews · doi:10.1152/physrev.00024.2006 · Cited by 1,107
Body Mass Index, Metabolic Syndrome, and Risk of Type 2 Diabetes or Cardiovascular Disease
Meigs, J. B., Wilson, P. W. F., Fox, C. S., Vasan, R. S., Nathan, D. M., SULLIVAN, L. M., & D’Agostino, R. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0594 · Cited by 1,088
Nissen, S. E., Nicholls, S. J., Wolski, K., Nesto, R., Kupfer, S., Perez, A., Jure, H., De Larochellière, R., Staniloae, C. S., Mavromatis, K., et al. (2008) · JAMA · doi:10.1001/jama.299.13.1561 · Cited by 850
Thiazolidinedione Use, Fluid Retention, and Congestive Heart Failure
Nesto, R. W., Bell, D. S. H., Bonow, R. O., Fonseca, V. A., Grundy, S. M., Horton, E. S., Winter, M. L., Porte, D., Semenkovich, C. F., Smith, S. E., et al. (2003) · Circulation · doi:10.1161/01.cir.0000103683.99399.7e · Cited by 831
Dapagliflozin improves muscle insulin sensitivity but enhances endogenous glucose production
Merovci, A., Solis-Herrera, C., Daniele, G., Eldor, R., Fiorentino, T. V., Tripathy, D., Xiong, J., Perez, Z., Norton, L., Abdul-Ghani, M. A., et al. (2014) · Journal of Clinical Investigation · doi:10.1172/jci70704 · Cited by 795
Kaur, R., Kaur, M., & Singh, J. (2018) · Cardiovascular Diabetology · doi:10.1186/s12933-018-0763-3 · Cited by 790
Pioglitazone for Diabetes Prevention in Impaired Glucose Tolerance
DeFronzo, R. A., Tripathy, D., Schwenke, D. C., Banerji, M., Bray, G. A., Buchanan, T. A., Clement, S. C., Henry, R. R., Hodis, H. N., Kitabchi, A. E., et al. (2011) · New England Journal of Medicine · doi:10.1056/nejmoa1010949 · Cited by 766
Lago, R. M., Singh, P. P., & Nesto, R. W. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61514-1 · Cited by 710
Therapeutic roles of peroxisome proliferator-activated receptor agonists
Staels, B., & Fruchart, J.-C. (2005) · Diabetes · doi:10.2337/diabetes.54.8.2460 · Cited by 646
Willson, T. M., Cobb, J. E., Cowan, D. J., Wiethe, R. W., Correa, I. D., Prakash, S. R., Beck, K. D., Moore, L. B., Kliewer, S. A., & Lehmann, J. M. (1996) · Journal of Medicinal Chemistry · doi:10.1021/jm950395a · Cited by 637
Nauck, M. A., Meier, J. J., Cavender, M. A., Abd El Aziz, M., & Drucker, D. J. (2017) · Circulation · doi:10.1161/circulationaha.117.028136 · Cited by 582
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Graham, D. J., Ouellet‐Hellstrom, R., MaCurdy, T. E., Ali, F. N., Sholley, C., Worrall, C. M., & Kelman, J. A. (2010) · JAMA · doi:10.1001/jama.2010.920 · Cited by 512
Wilcox, R., Bousser, M.-G., Betteridge, D. J., Schernthaner, G., Pirags, V., Kupfer, S., & Dormandy, J. (2007) · Stroke · doi:10.1161/01.str.0000257974.06317.49 · Cited by 475
Insulin resistance and pancreatic cell failure
Kasuga, M. (2006) · Journal of Clinical Investigation · doi:10.1172/jci29189 · Cited by 433
Htike, Z. Z., Zaccardi, F., Papamargaritis, D., Webb, D. R., Khunti, K., & Davies, M. J. (2016) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12849 · Cited by 423
Obesity, Inflammation, and Insulin Resistance – A Mini-Review
Zeyda, M., & Stulnig, T. M. (2009) · Gerontology · doi:10.1159/000212758 · Cited by 373
Nathan, D. M., Buse, J. B., Davidson, M. B., Ferrannini, E., Holman, R. R., Sherwin, R., & Zinman, B. (2007) · Diabetes Care · doi:10.2337/dc08-9016 · Cited by 324
Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes
Lewis, J. D., Habel, L. A., Quesenberry, C. P., Strom, B. L., Peng, T., Hedderson, M. M., Ehrlich, S. F., Mamtani, R., Bilker, W., Vaughn, D. J., et al. (2015) · JAMA · doi:10.1001/jama.2015.7996 · Cited by 320
Activation of Human Peroxisome Proliferator-Activated Receptor (PPAR) Subtypes by Pioglitazone
Sakamoto, J., Kimura, H., Moriyama, S., Odaka, H., Momose, Y., Sugiyama, Y., & Sawada, H. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3868 · Cited by 313
Vaccaro, O., Masulli, M., Nicolucci, A., Bonora, E., Del Prato, S., Maggioni, A. P., Rivellese, A. A., Squatrito, S., Giorda, C. B., Sesti, G., et al. (2017) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30317-0 · Cited by 292
Erdmann, E., Charbonnel, B. H., Wilcox, R. G., Skene, A. M., Massi‐Benedetti, M., Yates, J., Tan, M. H., Spanheimer, R. G., Standl, E., Dormandy, J., et al. (2007) · Diabetes Care · doi:10.2337/dc07-0717 · Cited by 290
Neumann, A., Weill, A., Ricordeau, P., Fagot, J. P., Alla, F., & Allemand, H. (2012) · Diabetologia · doi:10.1007/s00125-012-2538-9 · Cited by 284
PPARγ and the Treatment of Insulin Resistance
Olefsky, J. M., & Saltiel, A. R. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00306-4 · Cited by 280
Choi, D., Kim, S., Choi, S. H., Ko, Y., Ahn, C. W., Jang, Y., Lim, S.-K., Lee, H., & Soo, B. (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2654 · Cited by 243
Pioglitazone use and risk of bladder cancer: Population based cohort study
Tuccori, M., Filion, K. B., Yin, H., Yu, O. H., Platt, R. W., & Azoulay, L. (2016) · BMJ · doi:10.1136/bmj.i1541 · Cited by 237
Safety and Tolerability of Pioglitazone in High-Risk Patients with Type 2 Diabetes
Dormandy, J., Bhattacharya, M., & van Troostenburg, A. (2009) · Drug Safety · doi:10.2165/00002018-200932030-00002 · Cited by 228
Use of Thiazolidinediones and Risk of Heart Failure in People With Type 2 Diabetes
Delea, T. E., Edelsberg, J., Hagiwara, M., Oster, G., & Phillips, L. S. (2003) · Diabetes Care · doi:10.2337/diacare.26.11.2983 · Cited by 216
Dargie, H. J., Hildebrandt, P. R., Riegger, G. A. J., McMurray, J. J. V., McMorn, S. O., ROBERTS, J. N., Zambanini, A., & Wilding, J. P. H. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2006.10.077 · Cited by 205
Insulin Resistance and Its Treatment by Thiazolidinediones
Lebovitz, H. E. (2001) · Recent Progress in Hormone Research · doi:10.1210/rp.56.1.265 · Cited by 181
Self-citationDeeg, M. A., Buse, J. B., Goldberg, R. B., Kendall, D. M., Zagar, A. J., Jacober, S. J., Khan, M. A., Perez, A. T., Tan, M. H., & on behalf of the GLAI Study Investigators (2007) · Diabetes Care · doi:10.2337/dc06-1903 · Cited by 180
Gervois, P. P., Fruchart, J., & Staels, B. (2007) · Nature Clinical Practice Endocrinology & Metabolism · doi:10.1038/ncpendmet0397 · Cited by 159
Pioglitazone for Secondary Stroke Prevention: A Systematic Review and Meta-Analysis
Lee, M., Saver, J. L., Liao, H.-W., Lin, C.-H., & Ovbiagele, B. (2017) · Stroke · doi:10.1161/strokeaha.116.013977 · Cited by 147
Thiazolidinedione Drugs and Cardiovascular Risks
Kaul, S., Bolger, A. F., Herrington, D. M., Giugliano, R. P., & Eckel, R. H. (2010) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2010.02.014 · Cited by 143
Insulin-Sensitive and Insulin-Resistant Variants in NIDDM
Banerji, M. A., & Lebovitz, H. E. (1989) · Diabetes · doi:10.2337/diab.38.6.784 · Cited by 134
Self-citationPioglitazone and Risk for Bone Fracture: Safety Data from a Randomized Clinical Trial
Viscoli, C. M., Inzucchi, S. E., Young, L. H., Insogna, K. L., Conwit, R., Furie, K. L., Gorman, M., Kelly, M. A., Lovejoy, A. M., Kernan, W. N., et al. (2016) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2016-3237 · Cited by 124
Revisiting the Rosiglitazone Story — Lessons Learned
Rosen, C. J. (2010) · New England Journal of Medicine · doi:10.1056/nejmp1008233 · Cited by 123
Thiazolidinedione Drugs and Cardiovascular Risks
Kaul, S., Bolger, A. F., Herrington, D. M., Giugliano, R. P., & Eckel, R. H. (2010) · Circulation · doi:10.1161/cir.0b013e3181d34114 · Cited by 121
Gerstein, H. C., Ratner, R. E., Cannon, C. P., Serruys, P. W. J. C., Garcia-Garcia, H., van Es, G., Kolatkar, N. S., Kravitz, B. G., Miller, D. M., Huang, C., et al. (2010) · Circulation · doi:10.1161/circulationaha.109.881003 · Cited by 102
Treatment of insulin resistance in diabetes mellitus
Lebovitz, H. E., & Banerji, M. A. (2004) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2004.02.051 · Cited by 96
Self-citationChen, X., He, Z., Zhou, Z., Yang, T., Zhang, X., Yang, Y., Duan, W., & Zhou, S. (2015) · Clinical and Experimental Pharmacology and Physiology · doi:10.1111/1440-1681.12455 · Cited by 91
Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis
Filipova, E. P., Uzunova, K. H., Kalinov, K., & Vekov, T. Y. (2017) · Diabetes Therapy · doi:10.1007/s13300-017-0273-4 · Cited by 88
Effects of TZD use and discontinuation on fracture rates in ACCORD bone study
Schwartz, A. V., Chen, H., Ambrosius, W. T., Sood, A., Josse, R. G., Bonds, D. E., Schnall, A. M., Vittinghoff, E., Bauer, D. C., Banerji, M. A., et al. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2015-1215 · Cited by 85
Bach, R. G., Brooks, M. M., Lombardero, M., GENUTH, S. M., Donner, T. W., Garber, A. J., Kennedy, L., Monrad, E. S., Pop‐Busui, R., Kelsey, S. F., et al. (2013) · Circulation · doi:10.1161/circulationaha.112.000678 · Cited by 65
The TIDE Trial Investigators (2011) · Diabetologia · doi:10.1007/s00125-011-2357-4 · Cited by 61
Horita, S., Nakamura, M., Satoh, N., Suzuki, M., & Seki, G. (2015) · PPAR Research · doi:10.1155/2015/646423 · Cited by 61
Young, L. H., Viscoli, C. M., Schwartz, G. G., Inzucchi, S. E., Curtis, J. P., Gorman, M., Furie, K. L., CONWIT, R. A., Spatz, E. S., Lovejoy, A. M., et al. (2018) · Circulation · doi:10.1161/circulationaha.118.034763 · Cited by 53
Rosiglitazone (Avandia) and pioglitazone (Actos) and heart failure.
Wooltorton, E. (2002) · PubMed Central · Cited by 50
Translating aetiological insight into sustainable management of type 2 diabetes
Taylor, R., & Barnes, A. C. (2017) · Diabetologia · doi:10.1007/s00125-017-4504-z · Cited by 46
Hoffmann, B. R., El‐Mansy, M. F., Sem, D. S., & Greene, A. S. (2012) · Journal of Medicinal Chemistry · doi:10.1021/jm301204r · Cited by 41
Aguilar, D. A., Bozkurt, B., Pritchett, A. M., Petersen, N. J., & Deswal, A. M. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.01.096 · Cited by 35
Does Thiazolidinedione therapy exacerbate fluid retention in congestive heart failure?
Goltsman, I., Khoury, E. E., Winaver, J. M., & Abassi, Z. A. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.09.007 · Cited by 33
Rosiglitazone, Myocardial Ischemic Risk, and Recent Regulatory Actions
Bourg, C. A., & Phillips, B. B. (2012) · Annals of Pharmacotherapy · doi:10.1345/aph.1q400 · Cited by 29
Panel Recommends Easing Restrictions on Rosiglitazone Despite Concerns About Cardiovascular Safety
Mitka, M. (2013) · JAMA · doi:10.1001/jama.2013.8141 · Cited by 26
Kernan, W. N., Viscoli, C. M., Dearborn, J. L., Kent, D. M., CONWIT, R. A., Fayad, P. B., Furie, K. L., Gorman, M., Guarino, P., Inzucchi, S. E., et al. (2017) · JAMA Neurology · doi:10.1001/jamaneurol.2017.2136 · Cited by 24
Rosiglitazone and the Case for Safety Over Certainty
Juurlink, D. N. (2010) · JAMA · doi:10.1001/jama.2010.954 · Cited by 23
Rosiglitazone treatment and cardiovascular disease in the V eterans A ffairs D iabetes Trial
Florez, H. J., Reaven, P. D., Bahn, G., MORITZ, T. E., Warren, S., Marks, J., Reda, D. J., Duckworth, W. C., Abraira, C., Hayward, R. A., et al. (2015) · Diabetes Obesity and Metabolism · doi:10.1111/dom.12487 · Cited by 21
PPARγ Agonist-Induced Fluid Retention Depends on αENaC Expression in Connecting Tubules
Fu, Y., Gerasimova, M., Batz, F., Kuczkowski, A., Alam, Y., Sanders, P. W., Ronzaud, C., Hümmler, E., & Vallon, V. (2014) · The Nephron journals/Nephron journals · doi:10.1159/000370254 · Cited by 18
Pioglitazone (Actos) and bladder cancer: Legal system triumphs over the evidence
Davidson, M. B. (2016) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2016.04.004 · Cited by 17
Berthet, S., Olivier, P., Montastruc, J., & Lapeyre‐Mestre, M. (2011) · BMC Clinical Pharmacology · doi:10.1186/1472-6904-11-5 · Cited by 13
Schneider, C. A., Pfister, R., & Erdmann, E. (2010) · Herz · doi:10.1007/s00059-010-3337-z · Cited by 7
A NEW WHOLE WHEAT IRRADIATED BISCUIT, CONTAINING VITAMINS AND MINERAL ELEMENTS.
Tisdall, F. F., Drake, T. G. H., Summerfeldt, P., & Brown, A. (1930) · PubMed Central · Cited by 7
Leier, C. V., & Haas, G. J. (2007) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2007.04.026 · Cited by 6
Long-term Risk of Cardiovascular Events With Rosiglitazone: A Meta-analysis
Singh, S., Loke, Y. K., & Furberg, C. D. (2007) · JAMA · doi:10.1001/jama.298.10.1189 · Cited by 5
Research works printed but not linked: 2
- Lebovitz HE. In: Wass JAH, Stewart PM, editors. The metabolic syndrome chapter 13.36 in Oxford textbook of endocrinology and diabetes 2nd Edition. Oxford: OXFORD University Press; 2011.
- Gervois P, Fruchart J-C, Staels B. Drug insight: mechanisms of action and therapeutic applications for agonists of peroxisome proliferator-activated receptors. Nat Clin Pract Endocrinol Metab. 2007;3:145–55. · DOI
Cited by
Sorted by citations
Type II diabetes mellitus: a review on recent drug based therapeutics.
Padhi, S., Nayak, A. K., & Behera, A. (2020) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2020.110708 · Cited by 726
Fleishman, J. S., & Kumar, S. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01811-6 · Cited by 615
Bioactive compounds in anti-diabetic plants: from herbal medicine to modern drug discovery
Tran, N., Pham, B., & Le, L. (2020) · Biology · doi:10.3390/biology9090252 · Cited by 553
Lipid metabolism in sickness and in health: Emerging regulators of lipotoxicity
Yoon, H., Shaw, J. L., Haigis, M. C., & Greka, A. (2021) · Molecular Cell · doi:10.1016/j.molcel.2021.08.027 · Cited by 538
ACSL4 deficiency confers protection against ferroptosis-mediated acute kidney injury
Wang, Y., Zhang, M., Bi, R., Su, Y., Quan, F., Lin, Y., Yue, C., Cui, X., Zhao, Q., Liu, S., et al. (2022) · Redox Biology · doi:10.1016/j.redox.2022.102262 · Cited by 444
Metadata
- Authors
- Lebovitz, H. E.
- Affiliations
- SUNY Downstate Health Sciences University (US)
- Corresponding author
- Lebovitz, Harold E.
- Venue
- Current Diabetes Reports
- Published
- 2019-11-27
- Volume
- 19
- Issue
- 12
- Pages
- 151-151
- ISSN
- 1534-4827 (ISSN-L)
- 1539-0829
- PMC
- PMC6881429
- OpenAlex
- W2990309084
- Cited by
- 388
- References
- 85
- Citations by year
- 2026: 45 · 2025: 62 · 2024: 75 · 2023: 68 · 2022: 65 · 2021: 57 · 2020: 16
- FWCI
- 5.29
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Locations
- Current Diabetes Reports (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Peroxisome Proliferator-Activated Receptors
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
- Keywords
- thiazolidinediones, insulin resistance, type 2 diabetes, rosiglitazone, pioglitazone, cardiovascular risk, myocardial infarction, ischemic stroke, bladder cancer, congestive heart failure, edema, bone fractures, drug safety, generic drugs
- MeSH terms
- Rosiglitazone, Pioglitazone, Diabetes Mellitus, Type 2, Humans, Hypoglycemic Agents, Insulin Resistance, Thiazolidinediones
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
